Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;80(6):797-812.
doi: 10.1007/s00228-024-03648-y. Epub 2024 Mar 2.

Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data

Maaike M E Diesveld #  1 , Daniëlle W M Jacobs- Pijnenburg #  2 , Rianne A Weersink  3   4 , Ina Barzel  5 , Joost P H Drenth  6 , Ton Lisman  7 , Herold J Metselaar  8 , Margje H Monster-Simons  9   10 , Midas B Mulder  5 , Eline Okel  11 , Katja Taxis  12 , Sander D Borgsteede  13
Affiliations

Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data

Maaike M E Diesveld et al. Eur J Clin Pharmacol. 2024 Jun.

Abstract

Purpose: The popularity of direct oral anticoagulants (DOACs) is increasing among patients with cirrhosis. Cirrhosis has a major impact on the pharmacokinetics of drugs, potentially increasing adverse events. Safe use of drugs in cirrhosis requires a diligent risk-benefit analysis. The aim of this study is to develop practice recommendations for safe use of DOACs in cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data.

Methods: We conducted a systematic literature search to identify studies on pharmacokinetics, pharmacodynamics and safety of DOACs in cirrhosis. Data were collected and presented in summary tables by severity of cirrhosis using the Child-Turcotte-Pugh (CTP) classification. A multidisciplinary expert panel evaluated the results and classified the DOACs according to safety.

Results: Fifty four studies were included. All DOACs were classified as 'no additional risks known' for CTP A. For CTP B, apixaban, dabigatran and edoxaban were classified as 'no additional risks known'. Apixaban and edoxaban showed fewer adverse events in patients with cirrhosis, while dabigatran may be less impacted by severity of cirrhosis based on its pharmacokinetic profile. Rivaroxaban was classified as 'unsafe' in CTP B and C based on significant pharmacokinetic alterations. Due to lack of data, apixaban, dabigatran and edoxaban were classified as 'unknown' for CTP C.

Conclusion: DOACs can be used in patients with CTP A cirrhosis, and apixaban, dabigatran and edoxaban can also be used in CTP B. It is recommended to avoid rivaroxaban in CTP B and C. There is insufficient evidence to support safe use of other DOACs in CTP C cirrhosis.

Keywords: Cirrhosis; Direct oral anticoagulants; Drug safety; Evidence-based medicine; Hepatology; Pharmacodynamics; Pharmacokinetics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Anticoagulants in cirrhosis: main concerns.
    Campello E, Fabris L, Simioni P. Campello E, et al. Nat Rev Gastroenterol Hepatol. 2024 Dec;21(12):827-828. doi: 10.1038/s41575-024-00998-x. Nat Rev Gastroenterol Hepatol. 2024. PMID: 39394378 No abstract available.

References

    1. Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, Krag A, Laleman W, Gines P (2018) EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69(2):406–460. https://doi.org/10.1016/j.jhep.2018.03.024 . (In Eng) - DOI
    1. Lisman T et al (2021) The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost 19(4):1116–1122. https://doi.org/10.1111/jth.15239 . (In Eng) - DOI - PubMed - PMC
    1. Eikelboom J, Merli G (2016) Bleeding with direct oral anticoagulants vs warfarin: clinical experience. Am J Med 129(11s):S33-s40. https://doi.org/10.1016/j.amjmed.2016.06.003 . (In Eng) - DOI - PubMed
    1. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C (2022) Baveno VII - Renewing consensus in portal hypertension. J Hepatol 76(4):959–974. https://doi.org/10.1016/j.jhep.2021.12.022 . (In Eng) - DOI - PubMed
    1. Hoolwerf EW, Kraaijpoel N, Büller HR, van Es N (2018) Direct oral anticoagulants in patients with liver cirrhosis: A systematic review. Thromb Res 170:102–108. https://doi.org/10.1016/j.thromres.2018.08.011 . (In Eng) - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources